The study conducted by Su et al. 40 determined the pre-treatment counts of PD-L1+ circulating tumor cells (CTCs) in blood of 47 HCC patients treated with PD-1 ICI (such as sintilimab, camrelizumab, and tislelizumab) combined with locoregional therapy (intensity-modulated radiotherapy (IMRT)) and TKI (such as sorafenib, regorafenib, lenvatinib, apatinib, and anlotinib) and unraveled that low PD-L1+ CTC count (< 2) predicted higher ORR (sensitivity/specificity, 77%/67%; 57% vs. 17%, P value = 0.007) and longer median OS (NR vs. 10.8 months, P value = 0.001) than high PD-L1+ CTC count (≥ 2). The gene discussed is CD274; the disease is neoplasm.